



STANDARDIZED ONE PAGE PHARMACY PRIOR AUTHORIZATION FORM

Mississippi Division of Medicaid, Pharmacy Prior Authorization Unit, 550 High St., Suite 1000, Jackson, MS 39201

Magnolia Health/Envolv Pharmacy Solutions
Fax to: 1-877-386-4695 Ph: 1-866-399-0928
<https://www.magnoliahealthplan.com/providers/pharmacy.html>

UnitedHealthcare/OptumRx
Fax to: 1-866-940-7328 Ph: 1-800-310-6826
<http://www.uhcommunityplan.com/health-professionals/ms/pharmacy-program.html>

Molina Healthcare/CVS Caremark
Fax to: 1-844-312-6371 Ph: 1-844-826-4335
<http://www.molinahealthcare.com/providers/ms/medicaid/pages/home.aspx>

Medicaid Fee for Service/Gainwell Technologies
Fax to: 1-866-644-6147 Ph: 1-833-660-2402
<https://medicaid.ms.gov/providers/pharmacy/pharmacy-prior-authorization/>

BENEFICIARY INFORMATION	
Beneficiary ID: _____ - _____ - _____	DOB: ____/____/_____
Beneficiary Full Name: _____	
PRESCRIBER INFORMATION	
Prescriber's NPI: _____	
Prescriber's Full Name: _____	Phone: _____
Prescriber's Address: _____	FAX: _____
PHARMACY INFORMATION	
Pharmacy NPI: _____	
Pharmacy Name: _____	
Pharmacy Phone: _____	Pharmacy FAX: _____
CLINICAL INFORMATION	
Requested PA Start Date: _____ Requested PA End Date: _____	
Drug/Product Requested: _____ Strength: _____ Quantity: _____	
Days Supply: _____ RX Refills: _____ Diagnosis or ICD-10 Code(s): _____	
<input type="checkbox"/> Hospital Discharge <input type="checkbox"/> Additional Medical Justification Attached	
Medications received through coupons and/or samples are not acceptable as justification.	
PLEASE COMPLETE AND FAX DRUG SPECIFIC CRITERIA/ADDITIONAL DOCUMENTATION FORM FOUND BELOW	
<i>Prescribing provider's signature (signature and date stamps, or the signature of anyone other than the provider, are not acceptable)</i>	
I certify that all information provided is accurate and appropriately documented in the patient's medical chart.	
Signature required: _____	Date: _____
Printed name of prescribing provider: _____	

FAX THIS PAGE

PRIOR AUTHORIZATION DESCRIPTION

- Note annotations and respective definitions as described on "Hepatitis C Therapy PA Request Guidelines for Regimen Selection and Definitions" page



Hepatitis C Therapy PA Request Guidelines for Regimen Selection and Definitions

For beneficiaries meeting the criteria, the Mississippi Division of Medicaid (DOM) will approve Hepatitis C treatment PA requests as follows:

- The regimens listed for each clinical scenario below are the preferred regimens for MS Medicaid beneficiaries, based on clinical and cost considerations and are consistent with AASLD/IDSA guidelines.
<http://www.hcvguidelines.org/full-report-view>
- Most patients will qualify for the Simplified Treatment outlined as follows.** Information about simplified treatment at: <https://www.hcvguidelines.org/treatment-naive/simplified-treatment>.

WHO IS ELIGIBLE FOR SIMPLIFIED TREATMENT	WHO IS NOT ELIGIBLE FOR SIMPLIFIED TREATMENT
Adults (18+ years of age) with chronic hepatitis C (any genotype) who (please check appropriate boxes) : <ul style="list-style-type: none"> <input type="checkbox"/> Do NOT have cirrhosis by lab or clinical exam <input type="checkbox"/> Have NOT been treated in the past <input type="checkbox"/> Are NOT pregnant <input type="checkbox"/> Are HIV negative <input type="checkbox"/> Are Hepatitis B Surface Antigen negative <input type="checkbox"/> NO known or suspected hepatocellular carcinoma <input type="checkbox"/> NO prior liver transplantation 	<ul style="list-style-type: none"> • Prior hepatitis C treatment • Cirrhosis • HIV or Hepatitis B Surface Antigen positive • Current pregnancy • Known or suspected hepatocellular carcinoma • Prior liver transplantation <p>IF NOT ELIGIBLE SEE OPTIONS ON FOLLOWING PAGES</p>
<p>Preferred Simplified Treatment Regimens (check one)</p> <ul style="list-style-type: none"> <input type="checkbox"/> Mavyret (glecaprevir/pibrentasvir) 100/40 mg; three (3) tablets daily for 56 days (8 weeks) <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 84 days (12 weeks) 	

OR

- Pediatric formulations of direct acting antivirals (DAA) with FDA approval will be approved for those patients under the age of eighteen when used according to the table below for treatment naïve children as well as in accordance with current AASLD guidelines including for indication and age - Prior authorization is still required prior to the first dose.**

GT	Age (years)	Weight (kg)	Drug	Dose	Weeks
Any	3 to 11	< 20	Mavyret Oral Pellets	Three 50 mg/20 mg packets daily	8
		20 - <30	Mavyret Oral Pellets	Four 50 mg/20 mg packets daily	8
		30 - < 45	Mavyret Oral Pellets	Five 50 mg/20 mg packets daily	8
		45+	Mavyret Tablets	Three 100/40 tablets daily	8
	12+		Mavyret Tablets	Three 100/40 tablets daily	8
	≥ 6	≥ 30	sofosbuvir/velpatasvir 400/100 tablet	One tablet daily	12

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

Confidentiality Notice: This communication, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply telephone (1-877-537-0722) or fax (1-877-537-0720) and destroy all copies of the original message. 12/2/2022

PRIOR AUTHORIZATION DESCRIPTION



- *Note annotations and respective definitions as described on “Hepatitis C Therapy PA Request Guidelines for Regimen Selection and Definitions” page*

OR

- *Clinical rationale is provided for using a regimen that is beyond those within the current guidelines, or for selecting regimens using non-preferred drugs on the Mississippi Division of Medicaid Universal Preferred Drug List*

On the PA Request Form, which must be approved prior to the 1st dose, document the clinical condition supporting the requested regimen. Unless otherwise specified, you do not need to attach documentation to the form. You are attesting to the fact that documentation is available in the patient chart for all information you provide.

DEFINITIONS/ANNOTATIONS USED ON PA FORM:

▽ **Low Dose Ribavirin = 600 mg/day and increase as tolerated**

◇ **Ribavirin-Ineligible** (documentation exists in the patient’s chart for at least one of the following):

- Hypersensitivity to RBV
- History of severe or unstable cardiac disease
- Pregnant women and men with pregnant partners
- Diagnosis of hemoglobinopathy (e.g., thalassemia major, sickle cell anemia)
- Baseline platelet count < 70,000 cells/mm³
- ANC < 1500 cells/mm³
- Hb < 12 gm/ml in women or <13 g/dl in men

RENAL DYSFUNCTION Patients with CrCl <50 ml/mm should not be treated with ribavirin.

Preferred Direct Acting Antivirals

Mavyret (glecaprevir/pibrentasvir) 300/120 mg
sofosbuvir/velpatasvir 400/100 mg

Non-Preferred Direct Acting Antivirals

Harvoni (ledipasvir/sofosbuvir) 90/400 mg
Sovaldi (sofosbuvir) 400 mg
ledipasvir/sofosbuvir 90/400 mg

Pediatric Indicated Direct Acting Antiretrovirals (FDA approved age ranges and indications ONLY)

Mavyret (glecaprevir/pibrentasvir) 400/100 mg
Mavyret Oral Pellets (glecaprevir/pibrentasvir) 50/20mg
Epclusa 200/50 mg tablet
Harvoni (ledipasvir/sofosbuvir) 45/200 mg tablet
Harvoni (ledipasvir/sofosbuvir) 90/400 mg tablet
Harvoni 33.75/150 mg pellet pak
Harvoni 45/200 mg pellet pak
Sovaldi (sofosbuvir) 200 mg
sofosbuvir/velpatasvir 400/100 mg

Vosevi (sofosbuvir, velpatasvir, and voxilaprevir)
Epclusa (sofosbuvir/velpatasvir) 400/100 mg

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

Confidentiality Notice: This communication, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply telephone (1-877-537-0722) or fax (1-877-537-0720) and destroy all copies of the original message.
12/2/2022

PRIOR AUTHORIZATION DESCRIPTION

- Note annotations and respective definitions as described on “Hepatitis C Therapy PA Request Guidelines for Regimen Selection and Definitions” page



Preferred (most cost-effective) Regimens Listed Below. Not all available regimens are listed.

NOTE: Adult Guidelines have changed substantially; most recommendations are largely genotype non-specific; exceptions are noted in red

PLEASE CHECK REQUESTED REGIMEN

ADULT: Treatment naïve
No cirrhosis <ul style="list-style-type: none"><input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks (for GT5/6 and/or HIV/HCV co-infection, 12 weeks is recommended)<input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks
Compensated cirrhosis, HIV negative <ul style="list-style-type: none"><input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 8 weeks<input type="checkbox"/> sofosbuvir/velpatasvir 400/100, one tablet daily for 12 weeks (for GT3, add weight based RBV if Y93H positive)
Compensated cirrhosis, HIV positive <ul style="list-style-type: none"><input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks<input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks (for GT3, add weight based RBV if Y93H positive)
ADULT: Treatment experienced (with or without compensated cirrhosis)
Sofosbuvir-based regimen <ul style="list-style-type: none"><input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 16 weeks
NS3/4 protease inhibitor inclusive regimen (e.g. Zepatier) <ul style="list-style-type: none"><input type="checkbox"/> Vosevi 400/100/100 mg, one tablet daily for 12 weeks
Mavyret <ul style="list-style-type: none"><input type="checkbox"/> Vosevi 400/100/100 mg, one tablet daily for 12 weeks (if compensated cirrhosis, add weight based RBV)
Vosevi or sofosbuvir + Mavyret <ul style="list-style-type: none"><input type="checkbox"/> Vosevi 400/100/100 mg, one tablet daily + weight based RBV for 24 weeks
GT 3 only: sofosbuvir/NS5A (e.g. Harvoni) <ul style="list-style-type: none"><input type="checkbox"/> Vosevi 400/100/100 mg, one tablet daily + weight based RBV for 12 weeks
ADULT: Re-infection of Allograft Liver after Transplant
DAA-treatment naïve, no decompensated cirrhosis <ul style="list-style-type: none"><input type="checkbox"/> Mavyret 100/40 mg, three (3) tablets daily for 12 weeks<input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg, one tablet daily for 12 weeks
DAA-treatment experienced, no decompensated cirrhosis <ul style="list-style-type: none"><input type="checkbox"/> Vosevi 400/100/100 mg, one tablet daily for 12 weeks
IF multiple negative baseline characteristics, consider <ul style="list-style-type: none"><input type="checkbox"/> Vosevi 400/100/100 mg, one tablet daily + low dose RBV for 12 weeks
Treatment naïve, decompensated cirrhosis <ul style="list-style-type: none"><input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg, one tablet daily + low dose RBV for 12 weeks
Treatment experienced, decompensated cirrhosis (Child-Pugh B or C ONLY) <ul style="list-style-type: none"><input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg, one tablet daily + low dose RBV for 24 weeks

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

Confidentiality Notice: This communication, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply telephone (1-877-537-0722) or fax (1-877-537-0720) and destroy all copies of the original message. 12/2/2022

PRIOR AUTHORIZATION DESCRIPTION

- *Note annotations and respective definitions as described on "Hepatitis C Therapy PA Request Guidelines for Regimen Selection and Definitions" page*



ADULT: Decompensated Cirrhosis
No prior sofosbuvir or NS5A failure <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg + weight-based RBV daily for 12 weeks (low dose RBV recommended for Child-Pugh class C cirrhosis) <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg daily for 24 weeks (will be approved only for patients with documented ineligibility for RBV)
Prior sofosbuvir or NS5A failure <input type="checkbox"/> sofosbuvir/velpatasvir 400/100 mg + weight-based RBV daily for 24 weeks (low dose RBV if Child-Pugh C)
Other Treatment Regimen requested
Genotype, treatment history, and extent of liver disease: _____ _____
Drug names, doses and durations: _____ _____
Clinical rationale for selecting regimens other than those outlined above: _____ _____

For unique patient populations with renal impairment or HIV: please refer to the current AASLD Guidelines for recommended treatments. <http://www.hcvguidelines.org/full-report-view>

If HIV positive: Please refer to the current AASLD Guidelines for potential drug interactions and recommended dosing adjustments.

DRUG INTERACTIONS

Reference: <http://hep-druginteractions.org/> provides clinically useful, reliable, and current evidence-based information on relevant drug interactions with hepatitis medications.

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

Confidentiality Notice: This communication, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply telephone (1-877-537-0722) or fax (1-877-537-0720) and destroy all copies of the original message. 12/2/2022

CRITERIA/ADDITIONAL DOCUMENTATION

HEPATITIS C

FAX THIS PAGE



BENEFICIARY INFORMATION

Beneficiary ID: _____ - _____ - _____ DOB: ____/____/____

Beneficiary Full Name: _____

Hepatitis C Therapy PA Request

Diagnosis / Treatment Status (check all that apply) *See Hepatitis-C PA description sheet for approval criteria and intolerance definitions.

For regimens other than Simplified Treatment, prescriber is, or has consulted with a gastroenterologist, hepatologist, ID specialist or other hepatic specialist. Requires consult within the past year with documentation of recommended regimen.

Active HCV infection verified by viral load within the last year: HCV RNA: _____ million IU/mL Date: _____

Genotype verified by lab: 1a 1b 2 3 4 5 6

<p>HIV status: <input type="checkbox"/> positive <input type="checkbox"/> negative (required)</p> <p><input type="checkbox"/> Patient has not taken amiodarone within 535 days (required if regimen includes Harvoni or Sovaldi)</p> <p><input type="checkbox"/> RBV-Ineligible reason: _____</p> <p>Hepatic fibrosis stage _____</p> <p>Last stage evaluation date: _____</p> <p>Method of cirrhosis/fibrosis stage: _____</p>	<p><input type="checkbox"/> Decompensated cirrhosis</p> <p><input type="checkbox"/> Compensated cirrhosis Child-Pugh Score and Date: _____</p> <p><input type="checkbox"/> Post-liver transplant Date: _____</p> <p><input type="checkbox"/> Hepatocellular carcinoma and awaiting a liver transplant: Transplant date: _____</p> <p><input type="checkbox"/> Not yet scheduled</p> <p><input type="checkbox"/> Dialysis __Yes/___No</p> <p><input type="checkbox"/> CrCl ____ mL/min Lab Date w/n last year: _____</p> <p><input type="checkbox"/> Screened for HEP-B and HIV prior to HEP-C treatment start</p> <p>▪ Date of last test: Hep B: ____/____/____ HIV: ____/____/____</p> <p>➤ Timing of the screening for Hep-B/HIV should be based on patient specific risk factors but lab result date must be provided and if > 1 year ago, it should be documented in the record as to why repeat testing is not clinically warranted. If the patient has had ongoing risk factors of any type, consider retesting in the month prior to HCV therapy. If positive, treatment must be considered per AASLD/IDSA and current NIH HIV guidelines.</p> <p>➤ Repeat screening should be patient specific.</p>
---	---

Patient is: Treatment naïve Relapser

If Relapser, then prior HCV Treatment: last two regimens, if any

Regimen 1: _____ Dates/duration of use: _____ Response: _____

Regimen 2: _____ Dates/duration of use: _____ Response: _____

Prior partial responder Prior null responder

Stopped prior therapy for other reason: _____

Regimen: _____ Dates/duration of use: _____ Response: _____

Social History (check all that apply)

Patient is ≥ 18 years of age **OR** meets current AASLD guidelines for treatment

Documentation (available if requested) of:

Counseling regarding abstinence from alcohol, IV drug use and education on how to prevent HCV transmission.

For women of childbearing potential and male patients with female partners of childbearing potential (for RBV regimens only):

Patient is not pregnant (or a male with a pregnant female partner) and not planning to become pregnant during treatment or within 6 months of stopping treatment.

Agreement that partners will use 2 forms of effective contraception during treatment and for at least 6 months after stopping tx.

Verification that monthly pregnancy tests will be performed throughout treatment.

Other Medications (OTC, Herbal and Prescription) Information

Drug name / strength	Frequency / instructions	Quantity	Refills

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

Confidentiality Notice: This communication, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply telephone (1-877-537-0722) or fax (1-877-537-0720) and destroy all copies of the original message 12/2/2022